BR112022016448A2 - Método para tratamento de doença do enxerto contra hospedeiro crônica - Google Patents

Método para tratamento de doença do enxerto contra hospedeiro crônica

Info

Publication number
BR112022016448A2
BR112022016448A2 BR112022016448A BR112022016448A BR112022016448A2 BR 112022016448 A2 BR112022016448 A2 BR 112022016448A2 BR 112022016448 A BR112022016448 A BR 112022016448A BR 112022016448 A BR112022016448 A BR 112022016448A BR 112022016448 A2 BR112022016448 A2 BR 112022016448A2
Authority
BR
Brazil
Prior art keywords
host disease
chronic graft
treatment
individual
versus host
Prior art date
Application number
BR112022016448A
Other languages
English (en)
Portuguese (pt)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900472A external-priority patent/AU2020900472A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022016448A2 publication Critical patent/BR112022016448A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022016448A 2020-02-19 2021-02-18 Método para tratamento de doença do enxerto contra hospedeiro crônica BR112022016448A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020900472A AU2020900472A0 (en) 2020-02-19 Method for treating chronic graft versus host disease
PCT/EP2021/054066 WO2021165420A1 (en) 2020-02-19 2021-02-18 Method for treating chronic graft versus host disease

Publications (1)

Publication Number Publication Date
BR112022016448A2 true BR112022016448A2 (pt) 2022-11-29

Family

ID=74701467

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016448A BR112022016448A2 (pt) 2020-02-19 2021-02-18 Método para tratamento de doença do enxerto contra hospedeiro crônica

Country Status (9)

Country Link
US (1) US20230097931A1 (https=)
EP (1) EP4106776A1 (https=)
JP (1) JP2023513847A (https=)
KR (1) KR20220143092A (https=)
CN (1) CN115361960A (https=)
AU (1) AU2021222342A1 (https=)
BR (1) BR112022016448A2 (https=)
CA (1) CA3168330A1 (https=)
WO (1) WO2021165420A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2024168161A1 (en) * 2023-02-08 2024-08-15 Mesoblast International Sarl Potency assay and manufacturing method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
KR20080105555A (ko) * 2007-05-31 2008-12-04 인하대학교 산학협력단 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
EP2324109B1 (en) * 2008-09-03 2016-10-26 Mesoblast, Inc. Expansion of haemopoietic precursors
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
ES2984009T3 (es) * 2013-11-04 2024-10-28 Isopogen Pty Ltd Método de cultivo celular
SG11201909856XA (en) * 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Also Published As

Publication number Publication date
JP2023513847A (ja) 2023-04-03
AU2021222342A1 (en) 2022-09-15
US20230097931A1 (en) 2023-03-30
EP4106776A1 (en) 2022-12-28
CN115361960A (zh) 2022-11-18
WO2021165420A1 (en) 2021-08-26
KR20220143092A (ko) 2022-10-24
CA3168330A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
BR112022020042A2 (pt) Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
BR112022009216A2 (pt) Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
BR112022024483A2 (pt) Métodos para tratar mieloma múltiplo
BR112022024420A2 (pt) Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
BR112019022901A2 (pt) precursor de linhagem mesenquimal ou células t com imunossupressão intensificada
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
CO2024009492A2 (es) Composición y método para inhibir la expresión de proteína lpa(apo(a))
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
JOP20200021A1 (ar) طرق للعلاج و/أو الوقاية من داء الطعم حيال الثوي و/أو نزف سنخي منتشر و/أو داء الانسداد الوريدي المرتبط بطعم خلية جذعية مكونة للدم
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
BR112022017560A2 (pt) Método para tratar doença inflamatória intestinal i
WO2020227689A8 (en) Oligosaccharide compositions and methods of use
BR112022017557A2 (pt) Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal
MA71277A1 (fr) Méthodes de traitement de l'obésité, du diabète et de la dysfonction hépatique
BR112023021825A2 (pt) Método para tratar síndrome da angústia respiratória aguda (sara) em pacientes específicos utilizando precursores de linhagem mesenquimal ou células tronco
BR112017024065A2 (pt) método para tratar insuficiência cardíaca avançada em um indivíduo humano
BR112022008700A2 (pt) Método para tratar ou prevenir uma doença falciforme, e, transplante de células hematopoiéticas imaturas e uma quantidade terapeuticamente eficaz de uma população isolada de células anti-terceiros não indutoras de doença do enxerto versus hospedeiro
AR121013A1 (es) Anticuerpos anti-cd40 y composiciones
BR112023016668A2 (pt) Terapia de gene de combinação para tratamento de câncer metastático
BR112023001049A2 (pt) Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética
MX2024009257A (es) Composiciones y metodos para inhibir la expresion de la proteina precalicreina (pkk).